Anti-Mouse CD54 (Clone YN1/1.7.4) – Purified in vivo PLATINUM™ Functional Grade

Clone YN1/1.7.4 is a monoclonal antibody targeting mouse CD54 (ICAM-1), most commonly used in vivo in mice to block CD54 function and study cell adhesion, leukocyte migration, and inflammatory processes.

Common in vivo applications of clone YN1/1.7.4 in mice include:

• Functional blockade of CD54 (ICAM-1): Used to inhibit the interaction between CD54 and its ligands (LFA-1 and Mac-1), which is critical for leukocyte adhesion and transmigration during immune responses and inflammation.
• Modulation of immune cell infiltration: Administration of YN1/1.7.4 in mouse models decreases neutrophil infiltration into inflammatory lesions and inhibits the production of pro-inflammatory cytokines such as CXCL1, IFNγ, and IL-17.
• Investigation of cell-cell adhesion mechanisms: Blocking CD54 with YN1/1.7.4 allows researchers to dissect the role of ICAM-1 in antigen presentation and immune cell interactions, especially in the context of inflammation or autoimmunity.
• Assessment of disease mechanisms: YN1/1.7.4 is employed in models of inflammatory diseases (e.g., arthritis, autoimmune conditions) to understand how CD54 contributes to pathology by facilitating immune cell migration and tissue infiltration.
• In vivo blocking/neutralization assays: The antibody is widely used in protocols requiring a specific blockade of CD54’s function to establish its role in leukocyte dynamics and tissue injury.

Additionally, YN1/1.7.4 is suitable for immunohistochemistry and flow cytometry analysis of mouse tissues, but its functional blocking application is most relevant for in vivo studies of immune processes.

In summary, the principal in vivo applications of clone YN1/1.7.4 in mice are as a functional blocking tool for CD54 to study leukocyte adhesion, migration, and immune regulation in models of inflammation and immune-mediated disease.

Frequently, YN1/1.7.4, a monoclonal antibody targeting mouse CD54 (ICAM-1), is used in conjunction with antibodies against common immune cell surface markers, such as CD3, CD4, CD8, CD19, CD11b, CD11c.

In typical research applications like flow cytometry and immunohistochemistry, investigators combine YN1/1.7.4 with the following antibodies or proteins to delineate immune cell types and states:

• CD3 (marker for T cells)
• CD4 (marker for helper T cells)
• CD8 (marker for cytotoxic T cells)
• CD19 (marker for B cells)
• CD11b (marker for monocytes/macrophages and some dendritic cells)
• CD11c (marker for dendritic cells)

These combinations enable identification of CD54 expression across various immune cell subsets, measurement of activation/adhesion status, and investigation of cell-cell interactions during immune responses.

Additionally, in functional studies examining adhesion, YN1/1.7.4 is often used with antibodies or proteins targeting LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18), which are key ligands for ICAM-1. These interactions are essential for T cell and leukocyte trafficking, so researchers may employ YN1/1.7.4 alongside:

• Anti-CD11a
• Anti-CD18
• Anti-CD11b

Some publications also mention combining YN1/1.7.4 with other endothelial antibodies such as clone 390, especially in imaging perfused tissue segments to analyze vascular boundaries and antibody capture efficacy.

Isotype controls and secondary antibodies are standard for specificity and detection, with rat IgG2b often matched for controls in studies employing YN1/1.7.4.

In summary, the most commonly paired antibodies/proteins with YN1/1.7.4 in the literature are:

• CD3, CD4, CD8, CD19, CD11b, CD11c (immune cell markers)
• CD11a, CD18, CD11b (adhesion molecules, LFA-1, Mac-1 ligands/partners)
• Clone 390 (another endothelial marker, in certain tissue imaging protocols)
• Isotype controls, typically Rat IgG2b

Pairing YN1/1.7.4 with these antibodies allows researchers to investigate immune cell phenotypes, cell adhesion, and tissue localization in complex immunological settings.

Clone YN1/1.7.4 is a rat monoclonal antibody extensively used in scientific research for specific targeting and functional blockade of mouse CD54 (ICAM-1), and its main citations reveal several consistent key findings:

• Functional Blockade: It effectively blocks the interaction between CD54/ICAM-1 and its integrin ligands, especially LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18), resulting in inhibition of cell-cell adhesion and immune cell recruitment.
• Suppression of Inflammatory and Immune Responses: In vivo studies using clone YN1/1.7.4 demonstrate its capacity to modulate inflammatory responses, block leukocyte endothelial transmigration, and thereby serve as a tool to study immune cell migration and CD54-dependent pathological processes such as inflammatory diseases and cancer.
• Imaging and Binding: The antibody is highly effective for imaging applications (including flow cytometry and immunohistochemistry) because it rapidly and specifically binds endothelial, monocyte, lymphocyte, and dendritic cell–expressing CD54/ICAM-1. Fluorescence imaging using AF488-labeled YN1/1.7.4 allows visualization of immune cell interactions and tissue-level adhesion molecule distribution.
• Antigen Presentation Modulation: By blocking ICAM-1, YN1/1.7.4 can alter antigen presentation processes in mouse models, influencing T cell activation and function.
• Technical Quality for In Vivo Use: Studies cite its ultra-low endotoxin content and high purity, which are essential for sensitive animal experiments, minimizing nonspecific immune activation while enabling precise evaluation of antibody-mediated effects.
• Epitope Specificity: Clone YN1/1.7.4 recognizes an epitope on mouse ICAM-1 distinct from other commonly used antibodies (e.g., eBioKAT-1), providing experimental flexibility and specificity for mechanistic studies.

These findings make YN1/1.7.4 a key tool for studying immune cell trafficking, inflammation, and barrier function across various mouse models used in immunology, oncology, and vascular biology.

Dosing regimens of clone YN1/1.7.4 (anti-mouse CD54/ICAM-1) vary depending on the mouse model, disease context, and experimental aim. There is no universal protocol, but published studies and supplier data provide typical regimens and methodologies.

Key variations in dosing regimens:

• Dose amount:
  Doses can vary widely. For example, in studies involving in vivo immune modulation, 100 μg per mouse administered intraperitoneally three times per week for two weeks has been reported. For vascular navigation and antibody capture, studies have tested doses from 800 ng to 1200 ng per perfused segment in ex vivo liver models.

• Dosing schedule:
  Some protocols use frequent, repeated dosing over weeks (e.g., 3x per week for 2 weeks). Shorter, single doses or acute perfusions are used in imaging or antibody capture studies.

• Administration method:
  The clone has been administered intraperitoneally (IP) for systemic immune modulation, as well as locally by perfusion for vascular or imaging studies in organ segments. The route is selected based on experimental needs (systemic immunology vs. local vascular manipulation).

• Mouse model and disease context:
  Variation is observed depending on the mouse strain (e.g., inbred, nude, immune competent) and disease context (e.g., cancer metastasis, inflammation, vascular studies).
  For example, colorectal cancer (CRC) liver metastasis models used doses designed to modulate liver vascular/immune responses.

• Optimization:
  Titration is recommended for all applications. Each investigator is advised to determine optimal dilution and schedule for their specific setting and model.

Example regimens from the literature:

Conclusions and best practice:

• Dosing regimens for clone YN1/1.7.4 must be tailored for each specific mouse model and research objective.
• Published studies recommend careful titration, route selection, and pilot experiments to identify effective and non-toxic doses for each new application.

If you need a protocol for a specific disease model or mouse strain, please clarify for more tailored dosing recommendations.